12th Congress of the European Hematology ... - Haematologica

12 th Congress of the European Hematology Association
receiving allogeneic/autologous stem cell transplantation. We analyzed
retrospectively the charts of all patients who underwent stem cell transplant
in 2005-2006 at Texas Tech University Health Science Center. The
charts of 36 patients were reviewed of which 21 received kepivance.
Decision to receive kepivance was judged by the treating physician.
Patients with high risk of developing mucositis from intensive
chemotherapy, older patients, type of conditioning regimen, and type of
transplant dictated which patient should receive kepivance. Conditioning
regimens in the kepivance group were as follows: high dose melphalan
(10); TBI, VP-16 and cyclophosphamide (CTX) (1); BCNU, VP-16
and CTX (2); fludarabine and melphalan (1); melphalan and VP-16 (1);
busulfan and fludarabine (6). Conditioning regimens in the non-kepivance
group were as follows: melphalan and busulfan (1); melphalan and
fludarabine (2); BCNU, VP-16 and CTX (4); high dose melphalan (8). Out
of 21 patients who received kepivance, 12 patients received autologous
transplant and 9 patients received allogeneic transplants. Of the 21
patients who received kepivance, 8 experienced grade II-III mucositis
compared to 3 of 15 patients in the non- kepivance group. No patients
in both groups experienced grade IV mucositis. In both groups 50% of
the patients required total parenteral nutrition (TPN). The average length
of stay in patients who received kepivance was 31 days vs. 36 days in
patients who did not receive kepivance. Day 100 mortality, in the kepivance
group was 5, all of whom received allogeneic transplant, whereas
there was only 1 death (who received allogeneic transplantation) in
the non-kepivance group. We concluded that kepivance reduces the hospital
stay in patients undergoing stem cell transplantation. However,
there were no noted benefits of kepivance in TPN requirement or the
incidence of mucositis. This may be due to physician bias in selecting
patients who should receive kepivance. High risk patients received kepivance.
All the 9 patients in the kepivance group who received allogeneic
transplant did not experience acute graft versus host disease. A
prospective randomized clinical trial is needed to confirm these results.
1221
NOT PUBLISHED
1222
ACUTE CORONARY SYNDROME AND THROMBOPHILIC POLYMORPHISM
M.R. Gutierrez-Tous
University Hospital Valme, SEVILLA, Spain
Background. The thrombophilic polymorphisms, Factor V G1691A (Leiden),
Prothrombin G20210A Mutation (PT G20210A) and C46T of Factor
XII gene, are genetic variants in relation to venous thrombotic desease;
in the arterial thrombosis and the acute coronary syndrome his mean had
not been established, because currently the dates in relation to thrombophilic
risk factor are contradictory. Aims. The objective of this study is
to define the prevalence in own people of the Phrotrombin 20210 Mutation,
the Factor V Leiden and C46T polymorphism in the Factor XII gene
in health people and patients with acute coronary syndrome and to establish
the thrombophilic risk factor respectively. Methods. A prospective
study case/control we were included 483 subjects (76 patients and 407
controls).
Table 1. Prevalence of thrombophilic polymorphism in acute coronary syndrome
and controls.
The patients are recruitment enter the survivals with acute coronary
syndrome, at lest three month after the event. The controls are healthy
persons, blood donors, they were included in the study voluntarily. In the
group of patients, 61 (80.3%) subjects are men and 15 (19.7%) are women;
in the controls, 271 (66.6%) subjects are men and 136 (33.4%) are women.
The median of age of the patients is 49.9 years (24-74) with typical deviation
12.8 at the moment of the event, 48 (63.2%) patients are 55 years
446 | haematologica/the hematology journal | 2007; 92(s1)
old or less, because this study is planning in young people; in the group
of the controls the median is 38.4 years (21-72) typical deviation 10.7.
The detection of the Prothrombin 20210 Mutation, the Factor V Leiden
and the polymorphism 46C/T of Factor XII gene, by PCR in real time, in
liquid phase, in a LightCycler (Roche diagnostics) thermal cycler was
made. Stadistical methodology, the descriptive was made by groups in
patients and controls; to estimate the risk by square-chi proof. Results. The
results of the prevalence of the polymorphisms, Factor V Leiden, Prothrombin
G20210A Mutation and C46T of Factor XII gene, in patients and
controls in the Table 1 are showed. The estimate risk to have got an acute
coronary syndrome in relation to genotype GA of the Prothrombin
G20210A Mutation is 2.8 (1.1-7.2) IC (95%) p=0.025. Conclusion. The Prothrombin
G20210A Mutation is a risk factor for acute coronary syndrome
Supported by research project : SAS 0037/2005
1223
PROGNOSTIC AND CLINICAL SIGNIFICANCE OF CELL CYCLE PROTEINS IN LEUKEMIC
CELLS IN CHILDREN WITH ACUTE LEUKEMIA
T. Astrelina, E. Osipova, E. Vladimirskaya
Research Institute of Pediatric Hematol, MOSCOW, Russian Federation
Background. The investigation of the cell cycle proteins may occur
very useful in understanding the mechanisms of cell resistance to
chemotherapy the biological basis for the therapy of leukemia. Aims. to
estimate the expression of several proteins involved in the cell cycle and
the regulation of cell proliferation in leukemic cells in cases in childhood
with acute leukemia. Methods. The material of the study-bone marrow
from 79 children with initial diagnosed ALL, 37 children with initial
diagnosed AML and 7 controls (leukocytes peripheral blood from
healthy donors). We studied the quantities of several proteins cyclindependent
kinases (cdk2 and cdk4) and cyclins (cyclin D, cyclin E), E2F1
and pRb by Western blotting. The rate of proliferating cells was analyzed
by flow cytometry, using nuclear cell proliferation-associated antigen
(Ki67). Results. The levels of expression of cyclin D, cyclin E, cdk2 and
cdk4 was much higher of initial B-ALL in children in comparison with
T-ALL, pro-B-ALL and controls(p